Investors Buy Shares of Becton Dickinson and (BDX) on Weakness

Traders bought shares of Becton Dickinson and Co (NYSE:BDX) on weakness during trading on Monday. $86.38 million flowed into the stock on the tick-up and $47.75 million flowed out of the stock on the tick-down, for a money net flow of $38.63 million into the stock. Of all companies tracked, Becton Dickinson and had the 23rd highest net in-flow for the day. Becton Dickinson and traded down ($0.51) for the day and closed at $246.20

A number of equities analysts recently commented on the company. Zacks Investment Research upgraded Becton Dickinson and from a “sell” rating to a “hold” rating in a research note on Wednesday, April 10th. ValuEngine downgraded Becton Dickinson and from a “buy” rating to a “hold” rating in a research note on Monday, April 1st. Piper Jaffray Companies lifted their price target on Becton Dickinson and to $274.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 5th. Barclays lifted their price target on Becton Dickinson and from $260.00 to $266.00 and gave the stock an “equal weight” rating in a research note on Monday. Finally, TheStreet upgraded Becton Dickinson and from a “c+” rating to an “a” rating in a research note on Tuesday, February 5th. One research analyst has rated the stock with a sell rating, five have issued a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $256.25.

The company has a debt-to-equity ratio of 0.83, a current ratio of 0.97 and a quick ratio of 0.62. The company has a market cap of $64.58 billion, a P/E ratio of 20.70, a P/E/G ratio of 1.74 and a beta of 1.21.

Becton Dickinson and (NYSE:BDX) last issued its earnings results on Tuesday, February 5th. The medical instruments supplier reported $2.70 EPS for the quarter, beating the Zacks’ consensus estimate of $2.58 by $0.12. The company had revenue of $4.16 billion during the quarter, compared to the consensus estimate of $4.10 billion. Becton Dickinson and had a return on equity of 14.65% and a net margin of 5.69%. Becton Dickinson and’s quarterly revenue was up 35.1% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.48 earnings per share. On average, research analysts forecast that Becton Dickinson and Co will post 12.08 EPS for the current fiscal year.

The firm also recently declared a quarterly dividend, which was paid on Friday, March 29th. Stockholders of record on Friday, March 8th were issued a dividend of $0.77 per share. The ex-dividend date of this dividend was Thursday, March 7th. This represents a $3.08 dividend on an annualized basis and a dividend yield of 1.35%. Becton Dickinson and’s dividend payout ratio (DPR) is presently 27.97%.

In other news, CEO Vincent A. Forlenza sold 11,340 shares of Becton Dickinson and stock in a transaction that occurred on Monday, February 25th. The stock was sold at an average price of $250.40, for a total transaction of $2,839,536.00. Following the sale, the chief executive officer now owns 227,250 shares of the company’s stock, valued at $56,903,400. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Vincent A. Forlenza sold 8,309 shares of Becton Dickinson and stock in a transaction that occurred on Friday, March 15th. The shares were sold at an average price of $255.13, for a total value of $2,119,875.17. Following the sale, the chief executive officer now directly owns 222,785 shares in the company, valued at approximately $56,839,137.05. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 29,684 shares of company stock worth $7,518,574. Corporate insiders own 0.12% of the company’s stock.

A number of large investors have recently made changes to their positions in the stock. CWM LLC increased its holdings in shares of Becton Dickinson and by 5.6% in the fourth quarter. CWM LLC now owns 830 shares of the medical instruments supplier’s stock valued at $187,000 after buying an additional 44 shares in the last quarter. Mitchell Mcleod Pugh & Williams Inc. lifted its position in Becton Dickinson and by 1.2% during the 4th quarter. Mitchell Mcleod Pugh & Williams Inc. now owns 4,123 shares of the medical instruments supplier’s stock worth $929,000 after acquiring an additional 47 shares during the last quarter. Abner Herrman & Brock LLC lifted its position in Becton Dickinson and by 4.5% during the 4th quarter. Abner Herrman & Brock LLC now owns 1,105 shares of the medical instruments supplier’s stock worth $249,000 after acquiring an additional 48 shares during the last quarter. Providence Capital Advisors LLC lifted its position in Becton Dickinson and by 0.5% during the 4th quarter. Providence Capital Advisors LLC now owns 10,240 shares of the medical instruments supplier’s stock worth $2,307,000 after acquiring an additional 48 shares during the last quarter. Finally, Cigna Investments Inc. New lifted its position in Becton Dickinson and by 0.6% during the 4th quarter. Cigna Investments Inc. New now owns 7,891 shares of the medical instruments supplier’s stock worth $1,778,000 after acquiring an additional 48 shares during the last quarter. 84.87% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: This piece was posted by The Lincolnian Online and is the property of of The Lincolnian Online. If you are accessing this piece on another publication, it was illegally copied and republished in violation of United States & international copyright and trademark law. The legal version of this piece can be accessed at https://www.thelincolnianonline.com/2019/04/17/investors-buy-shares-of-becton-dickinson-and-bdx-on-weakness.html.

About Becton Dickinson and (NYSE:BDX)

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.

Recommended Story: What is a Stop Order?

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.